Kanterman J et al., 2014-11-01: Human and mouse study of colorectal cancer chemotherapy finding that regimen matters: FOLFOX reduced immunosuppression while FOLFIRI increased MDSC-driven suppression and worsened outcomes.
some conventional colorectal cancer chemotherapy supports the immunosuppressive tumor microenvironment. A FOLFOX combined therapy reduced immunosuppression, whereas a FOLFIRI combined therapy enhanced immunosuppression.
Abstract
Kanterman J et al., 2014-11-01: Human and mouse study of colorectal cancer chemotherapy finding that regimen matters: FOLFOX reduced immunosuppression while FOLFIRI increased MDSC-driven suppression and worsened outcomes. This is the honest middle: it supports the book's mechanism for one regimen (FOLFIRI, 5-FU plus irinotecan) while contradicting any blanket statement, since FOLFOX went the other way. Comparator: FOLFOX vs FOLFIRI vs untreated. Funder/COI not in the abstract. Pairs directly against CHB-29, which used 5-FU alone.
